The objective of the study was to pharmacokinetic modification of controlled release tablets of Isradipine tablets designed to provide 24 hours drug release profile using varying proportion of Eudragit L-100 and HPMC Phthalate; Lactose monohydrate as matrix-forming material. The prepared matrix tablets showed satisfactory physicochemical properties where drug content was 99.19 % to 103.78 %, thickness was 3.23 mm to 3.36 mm, hardness was 3.37±0.13 to 3.51±0.20 kg/cm2, friability was less than 1% and % weight variation was within the standard pharmacopoeial limits of ±10% of the weight. Mathematical analysis of the release kinetics of the optimized formulation (F15) was best fitted in zero order kinetics (R2 = 0.982). The dissolution profiles of formulation FI4 and innovator product in multi media were compared in Phosphate buffer pH 6.8.Several kinetic models respectively. The stability data reveals that the FI4 showed a negligible change in drug content thickness, weight variation, hardness, friability and in vitro drug release for three months according to ICH guidelines. © 2019 Elsevier B.V., All rights reserved.